EP 0988280 A1 20000329 - HYDROXAMIC ACID COMPOUNDS HAVING ANTICANCER AND ANTI-PARASITIC PROPERTIES
Title (en)
HYDROXAMIC ACID COMPOUNDS HAVING ANTICANCER AND ANTI-PARASITIC PROPERTIES
Title (de)
HYDROXAMSÄUREVERBINDUNGEN DIE SICH ALS ANTIKREBS- UND ALS ANTIPARASITÄRE MITTEL EIGNEN
Title (fr)
COMPOSES D'ACIDE HYDROXAMIQUE AYANT DES PROPRIETES ANTICANCEREUSES ET ANTIPARASITAIRES
Publication
Application
Priority
- AU 9800431 W 19980605
- AU PO721997 A 19970606
Abstract (en)
[origin: WO9855449A1] The invention provides a hydroxamate or hydroxamic acid compound of general formula (Ia) or (Ib): HONH-[linker]-X<1>R<1>R<2> or (Ic): R<1>R<2>X<1>-[linker]-X<1>R<1>R<2>, in which X<1> is a polar group selected from the group consisting of -C=O; -COR<1>; -CF2; -CNH2; -CNR<1>; -SO2-; -P(O)(OH)-; -C=S; -CSR<1>; -C-COR<1>; -C-CONR<1>R<2> and -C-CH2OH; R<1> and R<2> are the same or different, and each is independently selected from the group consisting of H; OH; NH2; NHOH; substituted or unsubstituted, branched or unbranched alkyl, alkenyl, alkylamino, alkyloxy or arylalkyloxy; substituted or unsubstituted aryl, aryloxy or pyridino; substituted or unsubstituted arylamino, piperidino, cycloalkyl, cycloalkylamino, pyridineamino, 9-purine-6-amine, and thiazoleamino; or either R<1> or R<2> is absent; and the linker is a group having a backbone of 5 to 9 atoms, which may comprise 1, 2 or 3 amino acids, or a pharmaceutically acceptable salt, ester or derivative thereof. The compounds have the ability to selectively prevent the growth of a variety of human tumour cell types, without affecting growth of normal cells. The compounds of the invention also inhibit the growth of protozoan parasites.
IPC 1-7
C07C 259/04; C07C 259/06; C07C 259/08; C07C 259/10; C07K 5/04; C07D 209/44; C07D 209/48; C07D 217/22; C07D 217/24; C07D 217/14; C07D 217/16; A61K 38/06; A61K 38/05; A61K 38/12; A61K 31/16; A61K 31/165; A61K 31/38
IPC 8 full level
C07D 333/34 (2006.01); A61K 31/16 (2006.01); A61K 31/352 (2006.01); A61K 31/381 (2006.01); A61K 31/382 (2006.01); A61K 31/4035 (2006.01); A61K 31/47 (2006.01); A61K 31/472 (2006.01); A61K 38/00 (2006.01); A61K 45/00 (2006.01); A61P 17/06 (2006.01); A61P 17/16 (2006.01); A61P 31/04 (2006.01); A61P 33/02 (2006.01); A61P 35/00 (2006.01); C07C 259/06 (2006.01); C07C 259/10 (2006.01); C07C 275/44 (2006.01); C07D 215/02 (2006.01); C07D 217/24 (2006.01); C07D 311/22 (2006.01); C07D 311/58 (2006.01); C07D 335/06 (2006.01); C07K 5/065 (2006.01); C07K 5/08 (2006.01); C40B 40/02 (2006.01); C40B 40/04 (2006.01); C40B 50/06 (2006.01)
CPC (source: EP)
A61K 31/16 (2013.01); A61K 31/381 (2013.01); A61K 31/4035 (2013.01); A61P 17/06 (2017.12); A61P 17/16 (2017.12); A61P 31/04 (2017.12); A61P 33/02 (2017.12); A61P 35/00 (2017.12); C07C 259/06 (2013.01); C07K 5/06078 (2013.01); A61K 38/00 (2013.01); Y02A 50/30 (2017.12)
Citation (search report)
See references of WO 9855449A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9855449 A1 19981210; AU PO721997 A0 19970703; EP 0988280 A1 20000329; JP 2002513419 A 20020508
DOCDB simple family (application)
AU 9800431 W 19980605; AU PO721997 A 19970606; EP 98925331 A 19980605; JP 50113399 A 19980605